Andere Sprachen Purple Biotech Ltd Nasdaq

Aktien

A2QLTP

US74638P1093

PPBT

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 17.05.2024			% 5 Tage	% 1. Jan.
0,554 ^USD	+10,34 %		+5,50 %	-28,97 %

25.04.	Randomisierte Phase-2-Studie mit CM24 zur Behandlung von Bauchspeicheldrüsenkrebs von Purple Biotech Ltd. als Late-Breaking-Abstract-Posterpräsentation auf der ASCO-Jahrestagung 2024 ausgewählt	CI
14.03.	Purple Biotech meldet präklinischen Wirksamkeitsnachweis für seine Tribody-Plattformtechnologie	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting	25.04.
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024	28.03.
Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology	14.03.
Purple Biotech : Immediate Report	06.03.
6K:Fourth Quarter and Full-Year 2023 Financial Results	05.03.
Purple Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	05.03.
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results	05.03.
Purple Biotech Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	05.03.
Purple Biotech Presents Data of Its Phase 1 Head & Neck Cancer of NT219 in Combination with Cetuximab At ESMO TAT Congress 2024	27.02.
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024	27.02.
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial	13.02.
Purple Biotech Reaches Recommended Phase 2 Dose for NT219	01.02.
Purple Biotech Ltd. Announces Executive Changes	20.12.
Purple Biotech Ltd. Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial	14.12.
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial	14.12.
Papillary Thyroid Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	30.11.
Purple Biotech Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	21.11.
Purple Biotech Reports Third Quarter 2023 Financial Results	21.11.
Purple Biotech Fortifies NT219 Patent Protection	02.11.
Purple Biotech : Other Report or Announcement	31.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Purple Biotech Ltd Nasdaq

Aktien

A2QLTP

US74638P1093

PPBT

Andere Sprachen

Filter